Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDoris HansenUGUtkarsh GoelAAAimaz Afrough

Discussion

Loading...

Member takes

Overview

Observational analysis identified key adverse prognostic markers affecting progression-free survival in relapsed/refractory multiple myeloma patients treated with bispecific antibodies.

Key Points

  • Median progression-free survival was 7.7 months for the cohort, impacted by adverse prognostic markers including ECOG PS and ferritin levels.
  • Analyzing 943 treatment initiations revealed that elevated ferritin and low hemoglobin were significant predictors of poor outcomes.
  • The analysis considered various bispecific antibodies, focusing on their prognostic impact across diverse patient profiles.
  • These findings highlight the importance of monitoring adverse prognostic markers like ECOG and ferritin to improve treatment strategies.

Cite This Study

Hansen et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236daaahttps://doi.org/10.1182/blood-2025-4069
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing2025
  2. 2Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma2025 · 1 citations
  3. 3Real‑world matched comparison of talquetamab versus teclistamab in Relapsed/Refractory multiple myeloma2025
  4. 4Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients2025
  5. 5Talquetamab outcomes from practice outside of clinical trials: The bital study2025